GlassScriptPhysician profile
Kimberly C Forcinel
NPI 1124406400
$91,608.45
in general payments reported to CMS, 2019-2025
25 companies · $57K in 2025
The $57K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,975 · 2022: $2,778 · 2023: $7,867 · 2024: $22K · 2025: $57K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $60K · Food and Beverage: $12K · Consulting Fee: $9,438 · Travel and Lodging: $4,717 · Education: $323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $60,093.00 |
| Food and Beverage | $12,284.73 |
| Consulting Fee | $9,437.50 |
| Travel and Lodging | $4,717.20 |
| Education | $323.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $62,787.52 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $19,192.44 | 2021-2025 | Ingrezza |
| Abbvie INC. | $2,022.16 | 2021-2025 | |
| Alkermes, INC. | $1,589.46 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $1,114.92 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $957.88 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $856.68 | 2022-2025 | Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $400.53 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $326.22 | 2023-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $276.61 | 2021-2022 | |
| Abbott Laboratories | $260.92 | 2024-2025 | Freestyle Libre 3 |
| Indivior INC. | $230.97 | 2022-2024 | Perseris |
| Vanda Pharmaceuticals INC. | $228.16 | 2024-2025 | Fanapt |
| Tris Pharma INC | $152.20 | 2024 | Dyanavel Xr |
| Lundbeck LLC | $130.71 | 2021-2023 | Abilify Maintena |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $127.13 | 2025 | Omnipod |
| Ardelyx, INC. | $125.00 | 2025 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $125.00 | 2023 | Ultomiris |
| Neurelis, INC. | $125.00 | 2024 | Valtoco |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Sage Therapeutics, LLC | $120.00 | 2025 | |
| Gilead Sciences, INC. | $119.78 | 2024 | Epclusa |
| Glaxosmithkline, LLC. | $113.19 | 2023 | Arexvy |
| Medtronic, INC. | $57.45 | 2024 | Linq II |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $43.52 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Forcinel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.